Serum granulocyte macrophage-colony stimulating factor: A Tumor marker in colorectal carcinoma?

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 6, 2009, Pages 1021-1024

  Demirci, Umut ^a   Coskun, Ugur ^a   Sancak, Banu ^a   Ozturk, Banu ^a   Bahar, Burak ^a   Benekli, Mustafa ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Colorectal cancer; GM CSF; Tumor marker

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COLORECTAL TUMOR; FEMALE; HUMAN; LEUKOCYTE COUNT; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 77956632955     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Aharinejad S, Abraham D, Paulus P, et al (2002). Colonystimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res, 62, 5317.
2. Anagnostopoulos GK, Sakorafas GH, Kostopoulos P, et al (2005). Disseminated colon cancer with severe peripheral blood eosinophilia and elevated serum levels of interleukine- 2, interleukine-3, interleukine-5, and GM-CSF. J Surg Oncol, 89, 273-5.
3. Calatayud S, Warner TD, Breese EJ, et al (2002). Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. Cytokine, 20, 163-7.
4. Curry JM, Eubank TD, Roberts RD, et al (2008). M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One, 3, 3405.
5. Dranoff G, Jaffee E, Lazenby A, et al (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA, 90, 3539-43.
6. Dranoff G (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer, 4, 11-22.
7. Enzler T, Gillessen S, Manis JP, et al (2003). Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med, 197, 1213-9.
8. Eubank TD, Roberts RD, Khan M, et al (2009). Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res, 69, 2133-40.
9. Foti E, Ferrandina G, Martucci R, et al (1999). IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels. Oncology, 57, 211-5.
10. Gerharz CD, Reinecke P, Schneider EM, et al (2001). Secretion of GM-CSF and M-CSF by human renal cell carcinomas of different histologic types. Urology, 58, 821-7.
11. Gobert Gosse S, Bourgin C, Liu WQ, et al (2005). M-CSF stimulated differentiation requires persistent MEK activity and MAPK phosphorylation independent of Grb2-sos association and phosphatidylinositol 3-kinase activity. Cell Signal, 17, 1352-62.
12. Grabstein KH, Urdal DL, Tushinski RJ, et al (1986). Induction of macrophage tumouricidal activity by granulocyte macrophage colony stimulating factor. Science, 232, 506-8.
13. Hill AD, Redmond HP, Naama HA, et al (1996). Granulocyte macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery, 119, 178-85.
14. Himes SR, Sester DP, Ravasi T, et al (2006). The JNK are important for development and survival of macrophages. J Immunol, 176, 2219-28.
15. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
16. Katsumata N, Eguchi K, Fukuda M, et al (1996). Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res, 2, 553-9.
17. Kubota Y, Takubo K, Shimizu T, et al (2009). M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med, 206, 1089-102.
18. Lau AS, Lehman D, Geertsma FR, et al (1996). Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons. Pediatr Infect Dis J, 15, 563-75.
19. Lidor YJ, Xu FJ, Martínez-Maza O, et al (1993). Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res, 207, 332-9.
20. Lieschke GJ, Burgess AW (1992). Granulocyte colonystimulating factor and granulocyte-macrophage colonystimulating factor. N Engl J Med, 327, 28-35, 99-106.
21. Lin JM, Li B, Rimmer E, et al (2008). Enhancement of the antitumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside. Exp Hematol, 36, 319-28.
22. McDermott RS, Deneux L, Mosseri V, et al (2002) Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw, 13, 121-7.
23. Megyeri P, Sadowska J, Issekutz TB, et al (1990). Endotoxin stimulated human macrophages produce a factor that induces polymorphonuclear leucocyte infiltration and is distinct from interleukin-1, tumour necrosis factor alpha and chemotactic factors. Immunology, 69, 155-61.
24. Mroczko B, Szmitkowski M, Wereszczyska-Siemiatkowska U, et al (2007). Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. Int J Colorectal Dis, 22, 33-8.
25. Nakada T, Sato H, Inoue F, et al (1996). The production of colony stimulating factors by thyroid carcinoma is associated with marked neutrophilia and eosinophilia. Intern Med, 35, 815-20.
26. Natori T, Sata M, Washida M, et al (2002). G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun, 297, 1058-61.
27. Ragnhammar P (1996). Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Med Oncol, 13, 167-76.
28. Rutkowski P, Kaminska J, Kowalska M, et al (2002). Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer, 100, 463-71.
29. Scholl SM, Bascou CH, Mosseri V, et al (1994). Circulating Levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer, 69, 349-56.
30. Scholl SM, Lidereau R, de la Rochefordiere A, et al (1996). Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat, 39, 275-83.
31. Schwager I, Jungi TW (1994). Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood, 83, 152-60.
32. Shantha Kumara SM, Kirman I, Feingold D, et al (2008). Perioperative GMCSF limits the proangiogenic plasma protein changes associated with colorectal cancer resection. Eur J Surg Oncol, 35, 295-301.
33. Watanabe M, Ono K, Ozeki Y, et al (1998). Production of granulocyte macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Jpn J Clin Oncol, 28, 559-62.